UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of October 2011
Commission File Number: 001-31368
SANOFI
(Translation of registrant’s name into English)
174, avenue de France, 75013 Paris, FRANCE
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ¨ No x
If “Yes” marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-
In October 2011, Sanofi issued the press releases attached hereto as Exhibits 99.1 to 99.4 which are incorporated herein by reference.
Exhibit List
| Exhibit No. |
Description | |
| Exhibit 99.1 |
Press release dated October 05, 2011: Investigational Oral Multiple Sclerosis Therapy Teriflunomide (Aubagio™) Significantly Reduced Relapse Rate, Disability Progression and Disease Activity | |
| Exhibit 99.2 |
Press release dated October 18, 2011: Sanofi and its subsidiary Genzyme to Feature More than 20 Data Presentations at the ECTRIMS/ACTRIMS Congress | |
| Exhibit 99.3 |
Press release dated October 20, 2011: Oral Therapy Teriflunomide (Aubagio™) Significantly Reduces Relapses Leading to Hospitalization of Patients with Multiple Sclerosis | |
| Exhibit 99.4 |
Press release dated October 22, 2011: Alemtuzumab (Lemtrada™) Significantly Reduces Relapses in Multiple Sclerosis vs Interferon Beta-1a in a Phase III Study | |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Dated: October 25, 2011 | SANOFI | |||||
| By | /S/ John Felitti | |||||
| Name: | John Felitti | |||||
| Title: | Associate Vice President, | |||||
| Corporate Law, Financial & Securities Law | ||||||
3
Exhibit Index
| Exhibit No. |
Description | |
| Exhibit 99.1 |
Press release dated October 05, 2011: Investigational Oral Multiple Sclerosis Therapy Teriflunomide (Aubagio™) Significantly Reduced Relapse Rate, Disability Progression and Disease Activity | |
| Exhibit 99.2 |
Press release dated October 18, 2011: Sanofi and its subsidiary Genzyme to Feature More than 20 Data Presentations at the ECTRIMS/ACTRIMS Congress | |
| Exhibit 99.3 |
Press release dated October 20, 2011: Oral Therapy Teriflunomide (Aubagio™) Significantly Reduces Relapses Leading to Hospitalization of Patients with Multiple Sclerosis | |
| Exhibit 99.4 |
Press release dated October 22, 2011: Alemtuzumab (Lemtrada™) Significantly Reduces Relapses in Multiple Sclerosis vs Interferon Beta-1a in a Phase III Study | |
4